Company / Accounts Receivable
Caris Life Sciences, Inc. Accounts Receivable History
FY2025-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$112.1M
FY2025
5-year range
$112.1M / $112.1M
FY2025-FY2025
Trend
-
vs FY2024
Sector context
#89 of 137
Health Care
What the data says
At $112M, Caris Life Sciences, Inc.'s accounts receivable ranks #89 of 137 in the Health Care sector.
Based on SEC 10-K filings.
$112M in FY2025.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#89 of 137 in Health CareTop 65% of 137This company $112.1M Sector average $1.3B
▼
-91.6% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $112.1M | - |
| FY2024 | - | - |
| FY2023 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026